key: cord-0749375-b0cyrehh authors: Martínez-Sánchez, N; De la Calle Fernández-Miranda, M; Bartha, JL title: SAFETY PROFILE OF TREATMENTS ADMINISTERED IN COVID 19 INFECTION IN PREGNANT WOMEN date: 2021-02-25 journal: Clin Invest Ginecol Obstet DOI: 10.1016/j.gine.2021.01.004 sha: 895331d51057e0014f302fcbfa62dc0c7af3393c doc_id: 749375 cord_uid: b0cyrehh SARS-CoV-2 infection has unexpectedly arrived in our society. In pregnant women, the situation has been similar to general population. Some drugs have been used empirically, and obstetricians have to consider whether the same treatments used in the general population were valid for pregnant women with severe disease, according to their safety profile for both the mother and the foetus. There has been a wide experience with the use of hydroxychloroquine and lopinavir/ritonavir in pregnant women. Tocilizumab and interferon beta could be used if benefits exceed risks. There is no experience using remdesivir in pregnancy. INTRODUCTION SARS-CoV-2 infection has come to our society unexpectedly. Currently there is still little knowledge of its behavior and progression in infected patients. The first cases were described in China in late December 2019 1 . While an effective vaccine or specific antiviral treatment is found, the rapid increase in the rate of serious infections and deaths has urged the scientific community to identify and use different drug options, sometimes on an experimental basis, in order to avoid worsening of infected patients and minimize their symptoms 2 . It is known that pregnancy predisposes women to respiratory complications of viral infection due to the physiological changes in their immune and cardiopulmonary system 3, 4 . Infection with SARS-CoV and MERS-CoV can be responsible for severe complications during pregnancy, including the need for endotracheal intubation, admission to an intensive care unit (ICU), renal failure and death 4, 5 . However, coronavirus disease (COVID 19) in pregnant women, have been similar to the general population in terms of contagiousness and affectation. The majority of pregnant women have mild disease (92%) 6 . Early data regarding pregnancy outcomes in COVID 19 is hopeful because vertical transmission and neonatal infection are rare 7 . Despite of this, obstetricians have to consider whether the same treatments used in the general population were valid for pregnant women with severe disease according to their safety profile for both the mother and the fetus. Because of pregnant women are usually excluded in therapeutic drugs and vaccine trials, the decision about choosing the best drug when it is needed, in terms of helpful and maternal-fetal security, are based on the experience of using these "antiCOVID 19 drugs" for other medical indications in pregnancy 8,9 . The objective is review the experience using this drugs in pregnancy, because they will inevitably receive therapies whenever they seem effective in nonpregnant patients and even under compassionate use 10 . Hydroxychloroquin is an antimalarial agent with anti-inflammatory and immnunomodulatory activities and it seems that it helps by inhibiting the exacerbation of pneumonia, improve lung imaging findings, promotes a virus-negative conversion and it shortens the duration of the COVID 19 8 . It is safe during pregnancy at doses of 200mg once or twice a day 10 and it is the medication of choice in women who need to maintain treatment during pregnancy for rheumatic diseases such as erythematosus systemic lupus (SLE), rheumatoid arthritis (RA) or Sjögren Syndrome (SS) 11, 12 . There is extensive good experience of use in these cases and pregnancy outcomes, in terms of miscarriages and fetal malformations, are similar between exposed pregnant women and not exposed to the drug 11, 13 . Chloroquine is an antimalarial drug and in vitro reduces coronavirus replication interfering with the angiotensin converting enzyme 2 (ACE2) receptor in the sars-cov-2 14 . Chloroquine crosses the placenta but no adverse pregnancy outcomes have been reported in exposed pregnant women 10,15 . It is an antiviral combination that belongs to the group of the protease inhibitors (PI). It is used in combination with two analog reverse transcriptase inhibitors (ARTI), in the socalled High Activity Antiretroviral Therapy (HAART) 16 . Lopinavir is a PI and ritonavir is an inhibitor of cytochrome p450 and is used as a booster to obtain therapeutic plasma concentrations 10 . It has in vitro and in vivo efficiency against SARS-CoV-1 and MERS infections, so they were considered as a treatment option for SARS-CoV-2 infection 17 , but first randomized trial reported no significant benefits 18 . We have extensive experience of its use in pregnant women with HIV infection. This pharmacological combination has a minimal transplacental passage. Recommended dosage is twice a day (it is not recommended to use them only once a day) and it will be considered to increase the dose in the third trimester if needed 16 . Pregnancy outcomes reported in women using lopinavir/ritonavir is similar to HIV women that do not taking it 19 . Tocilizumab (TCZ) is a recombinant and humanized IgG monoclonal antibody against IL-6. Exposure to the drug in the periconceptional period and/or the first few weeks of gestation does not appear to increase the risk of birth defects. A previous study has reported an increased risk of abortion, but the patients had other concomitant treatments such as methotrexate, so this outcome cannot be directly related to exposure to TCZ 20 . The use of tocilizumab is limited to severe COVID 19 infection. These patients have a cytokine storm which is a hyperinflammatory syndrome that lead to multiorgan failure. IL-6 participates in the SARS-CoV-2 cytokine storm, that is the reason this drug has been considered as a treatment for coronavirus disease 10, 21 . There is previous experience of use in pregnant women with rheumatic disease. Tocilizumab crosses the placental barrier and it is found in blood cord samples (89% of maternal plasma dosage) 22 . Although in some studies it has been reported an increased risk of maternal and fetal complications such as a preterm delivery (31.2%) and spontaneos abortions (21,7%). However, a direct relationship cannot be established with the use of the drug since it is abandoned in most cases at the beginning of gestation and co-medication, included methotrexate, was used by the prospectively ascertain cases 20, 23 . Those pregnant women who had to maintain or restart the drug due to clinical deterioration, had healthy newborns 23 . The expert recommendations are that if the benefits exceed the potential risk, the drug can be mantained along the pregnancy or it can be reintroduced. Although the data are scarce, this information may be useful in giving information to patients and doctors to make decisions 20, 23 . Infliximab is and anti-TNF drug, used for Chron`s disease also in pregnant women with wide experience 24 . It crosses the placenta in second and third trimesters, but no increased risk of congenital malformations has been reported. If necessary for control the disease it can be maintained until the end of the pregnancy 24 . In COVID 19 context, is under consideration for treating severe pneumonia 10 . Colchicine is an anti-inflammatory drug that could reduce cytokine storm and inflammatory cascade activation in severe COVID 19 disease. It is used in Behçet`s disease pregnant women and other autoimmune diseases (psoriasis, familiar Mediterranean fever…) with no increased risk of congenital malformations 25 . To date, no effectiveness has been reported for treating SARS-CoV-2 infection 10 . Other immunosuppressive drugs, such as, baricitinib and leflunomide are valued for COVID 19 disease but nowdays they are not recommended in pregnancy. Baricitinb, a Janus Kinasa (JAK) inhibitor has very few safety data in pregnant women and leflunomide, an immunosupressor, is teratogenic in animal models 10 . This drug is a cytokine from the interferon family with antiviral, antiproliferative and immunomodulatory effects 10 . There is experience on its use in pregnant women with multiple sclerosis (MS) to treat recurrent-remitting forms 26 . Interferon beta has been proposed as immunomodulatory treatment for control the massive inflammation in severe COVID 19 10 . Its use in pregnancy is not approved in the technical sheet, although there is no evidence of an increased risk of abortions or congenital malformations in women with MS exposed to interferon beta. Since the risk of outbreak in these patients decreases during pregnancy, it does not seem appropriate to keep the medication throughout it, however, if necessary due to the presence of significant activity, it can be administered throughout the pregnancy and it has not been seen fetal harm associated with the use of this drug. There are conflicting data regarding the risk of restricted intrauterine growth and premature delivery 27, 28 . Other drug used in the field of MS and also under investigation as a COVID 19 therapy is fingolimod, an immune modulator which prevents autoimmune reaction. There are safety data concerning risk of congenital malformations when used in MS pregnant women compared with general population 29 . Remdesivir is a nucleotide analogue inhibitor of RNA polymerase. It has ben used in the treatment of Ebola virus infection and experimentally in COVID 19 infection. There is no experience of use in pregnancy 30, 10 . Six patients with positive pregnancy test were treated with remdesivir in a clinical trial for treatment of Ebola virus infection, without subsequently referring to perinatal results in these patients in the event of non-death and continued pregnancy 31 . Other few published works on this matter do not refer to the use of the drug specifically in pregnant women. Considering its small molecular weight and its high protein-binding, it is expected that remdesivir could cross the placenta 10 . In the case of pregnant women infected with SARS-CoV-2 with severe symptoms or disease progression with the need of mechanic ventilation 2 , probably the use of remdesivir will be prioritized to avoid maternal worsening. 10 . And some drugs are under consideration for treating SARS-CoV-2 but not results have been reported yet (ribavirin, darunavir, nelfinavir, clevudine…) 10 . It is a macrolid antibiotic and is used is pregnancy and no increased risk of major congenital malformations have been reported 10, 33 . For COVID 19 disease it seems that the combination of azithromycin with hydroxychloroquine is more effective than this last one alone 34 . 10 . Drugs that modify the renin-angiotensin-aldosterone system are considered for treating COVID 19 disease (losartan, telmisartan…). This type of medications can damage fetal kidney, leading to renal failure. They may also affect placental functions increasing the risk of growth retardation in these fetuses. For all this reasons, they are not recommended in pregnancy 10, 35, 36 . Also contraindicated in pregnancy but under investigation for COVID 19 disease are drugs such as bevacizumab (antivascular endothelial growth factor antibody), thalidomide (antitumoral agent) 10 . Transfusion of immunoglobulins from patients who have recovered from the disease have been approved to treat critically ill patients and is also been evaluated in clinical trials 10 . Immunoglobulin G (IgG) can cross the placenta, mostly in second and third trimester, and they are very important preventing neonatal infections as a passive immunization. Lung maturation with corticosteroids should be managed according to the usual doses and recommendations of the obstetric and gynecology societies since the use of nonfluorinated corticosteroids does not ensure lung maturation 37 . Prednisone is inactivated by 11β-Hydroxysteroid dehydrogenase in the placenta and converts it into the relatively inactive forms, leaving no more than 10% of the active drug to reach the fetus 10, 38 . Fluorined glucocorticoids (betamethasone and dexamethasone) are considerably less well metabolized by the placenta. This is the reason they are used for treat the fetus 39 . Methylprednisolone and dexamethasone are being studied in prospective controlled trials for the management of SARS-Cov-2 infection 10 . Pregnancy and postpartum period are considered risk factors for venous thromboembolic disease (VTD) because of all physiological changes that ocurrs in coagulation status, cava venous compression by the uterus and tissue damage. VTE risk J o u r n a l P r e -p r o o f stratification is required to determine which women warrant pharmacological thromboprophylaxis 40 . Low molecular weight heparine (LMWH) is the preferred medication for the treatment and prevention of VTD in pregnancy 41 . Patients with severe COVID 19 disease have several risk factors for VTE (immobilization, respiratory failure, mechanical ventilation and central venous catheter use 42 . Also, VTE is more frequent in patients with pneumonia caused by pnemococcal or influenza infection 43 . The coexistence, therefore, of a COVID 19 infection in a pregnant woman makes it necessary the VTE evaluation for identify patients at high risk for VTE and provides them appropriate thromboprofilaxis 43, 44 . SARS-CoV-2 infection has revolutionized not only doctors and patients but the entire scientific community. Multiple papers have appeared in this regard that have tried to help the management of this unknown disease. Pregnant women have not been less and have also suffered COVID 19 disease, so we have seen the need to use empirical treatments for the disease and without data or with little safety data on its use in pregnancy 1 . Almost a year after the onset of the pandemic, we are acquiring some experience of use but there is still a long way to go since as on other occasions with other drugs, pregnant women are a group that are not included in clinical trials and that the use of drugs used to be out of label. Luckily, we are gaining safety in the use of certain drugs such as HIV protease inhibitors (lopinavir/ritonavir), interferon, hydroxichroloquine, azithromycin, colchicine, steroids, oseltamivir and some monoclonal antibodies (infliximab and possibly tocilizumab). In the other hand, there are known forbidden drugs becasuse of their teratogenicity (thalidomide and renin-angiotensin system blockers). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Drug treatment options for the 2019-new coronavirus (2019-nCoV) Pregnancy and Infection ISUOG Interim Guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium: information for healthcare professionals -an update Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection during pregnancy: Report of two cases & review of the literature Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China Outcome of coronavirus spectrum infections (SARS, MERS, COVID 1-19) during pregnancy: a systematic review and meta-analysis Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect Dis Consider pregnancy in covid-19 therapeutic drugs and vaccine trials Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019 BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids Control del embarazo en pacientes con lupus eritematoso sistémico y síndrome antifosfolípido. Parte 1: Infertilidad, preservación ovárica y valoración preconcepcional. Documento de consenso de la Sociedad Española de Ginecología y Obstetricia (SEGO), Sociedad Española de Medicina Interna (SEMI) y Sociedad Española de Reumatología (SER). Reumatol Clin Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group New insights into the antiviral effects of chloroquine Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study Documento de consenso para el seguimiento de la infección por el VIH en relación con la reproducción, embrazo, parto y profilaxis de la transmisión vertical del niño expuesto. Grupo de expertos de la Secretaría del Plan Nacional sobre el SIDA (SPNS), Grupo de Estudio de SIDA (GeSIDA)/Sociedad Española de Ginecología y Obstetricia (SEGO) y Sociedad Española de Infectología Pediátrica (SEIP) A systematic review of lopinavir therapy of SARS coronavirus and MERS coronavirus-a posible reference for coronavirus disease 19 treatment option A trial of lopinavir-ritonavir in adults hospitalized with severe Covid 19 Matenal and foetal outcomes among 4118 women with HIV infection treatet with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Irland Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Placental transfer of tocilizumab in a patient with rheumatoid arthritis The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: a report from the american gastroenterlogical association IBD parenthood Project working group The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancyrelated adverse events Treatment of multiple sclerosis during pregnancy-safety considerations Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure Compounds with therapeutic potential against novel respiratory 2019 coronavirus Controlled Trial of Ebola Virus Disease Therapeutics Oseltamivir use in pregnancy: risk of birth defects, preterm delivery, and small for gestational age infants Use of macrolids during pregnancy and the risk of birth defects: a population-based study Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label-non-randomized clinical trial Renin angiotensin system blocker fetopathy: a midwest pediatric nephrology consortium report Dysregulation of the placental renin-angiotensin system in human fetal growth restriction Amenaza de parto pretérmino Anti-inflammatory and immunosuppressive drugs and reproduction Placental 11b-hydroxysteroid dehydrogenase: a key regulatorof fetal glucocorticoid exposure Reducing risk of venous thromboembolism during pregnancy and the puerperium. Green-top guideline nº37.a. Royal College of Obstetrician and Gynecologists Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Association between pneumococcal pneumonia and venous thromboembolism in hospitalized patients: a nationwide population-based study Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19 We also considerer a third group of drugs, that one with insufficient safety pregnancy data, for example some IL-6 or IL-1 inhibitors, antivirals (remdesivir, favirapir…), ivermectin… but absence of data does not imply evidence of harm. So it is important to inform the pregnant women all the therapeutic options and agree with obstetricians and medical specialist the best drug in each case, taking into account the safety for the fetus but also for the mother.